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Abstract: Many potential inhaled medicines fail during development due to the induction of a highly
vacuolated or “foamy” alveolar macrophage phenotype response in pre-clinical studies. There is
limited understanding if this response to an inhaled stimulus is adverse or adaptive, and additionally
if it is a transient or irreversible process. The aim of this study was to evaluate whether high content
image analysis could distinguish between different drug-induced foamy macrophage phenotypes
and to determine the extent of the reversibility of the foamy phenotypes by assessing morphological
changes over time. Alveolar-like macrophages derived from the human monocyte cell line U937
were exposed for 24 h to compounds known to induce a foamy macrophage phenotype (amiodarone,
staurosporine) and control compounds that are not known to cause a foamy macrophage phenotype
in vitro (fluticasone and salbutamol). Following drug stimulation, the cells were rested in drug-free
media for the subsequent 24 or 48 h. Cell morphometric parameters (cellular and nuclear area,
vacuoles numbers and size) and phospholipid content were determined using high content image
analysis. The foamy macrophage recovery was dependent on the mechanism of action of the inducer
compound. Amiodarone toxicity was associated with phospholipid accumulation and morphometric
changes were reversed when the stimulus was removed from culture environment. Conversely cells
were unable to recover from exposure to staurosporine which initiates the apoptosis pathway. This
study shows that high content analysis can discriminate between different phenotypes of foamy
macrophages and may contribute to better decision making in the process of new drug development.
Keywords: foamy macrophages; high content analysis; phospholipidosis; apoptosis; macrophage
morphology; vacuolation
1. Introduction
Alveolar macrophages reside on the luminal surface of the alveolar space and are a normal
feature of the healthy lung [1]. They are the first immune cells in the airways to encounter incoming
pathogens, pollutants, or particles and play a crucial role in the initiation and resolution of immune
responses in the lung [1,2]. Alveolar macrophage responses are commonly observed in assessing the
safety of novel inhaled medicines during in vivo pre-clinical studies in rats [3]. Currently alveolar
macrophage responses in the lungs reported in pre-clinical studies are largely limited to observations
of an increase in the number of immune cells and the presence of cells with a highly vacuolated or
“foamy” morphology [3]. Novel inhaled medicines are often withdrawn from further development
due to concerns regarding the potential toxicity manifested by the presence of these foamy macrophage
observations in pre-clinical animal studies [3]. These “foamy” macrophage (FM) responses can be
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accompanied by additional abnormal lung tissue changes such as neutrophil infiltration or lymphocyte
degeneration [4]. The pathophysiology of foamy macrophage development is not explicit. The highly
vacuolated phenotype may be induced by a variety of cellular mechanisms including phagocytosis of
poorly soluble drug particles, stimulation of excess lung surfactant, impaired metabolism of intracellular
phospholipids, phagocytosis of surfactant phospholipids, apoptosis, and autophagy [3–5]. It is not
clear whether increased alveolar macrophage vacuolation should be classified as a permanent an
adverse or adaptive response [3,4]. The majority of in vitro toxicity testing is focused on the acute
effects of compounds at high concentrations [6]. However, this strategy may not reflect cell responses
during long-term exposures and low-dose toxicant effects. To better understand the foamy alveolar
macrophage phenomenon, it is necessary to study the timeframe over which increased vacuolation
occurs and whether there are morphological and/or biochemical markers, or thresholds of these
markers which indicate if the foamy macrophage phenotype is transient and reversible or a permanent
and irreversible process.
Pre-clinical safety of new inhaled medicines is predominantly assessed in vivo using rats. These
studies typically range from 30 to 90 day studies sacrificing a minimum of six rats per time point
over a range of concentrations, which in total require approximately 180 rats in a single drug efficacy
study [7]. Endpoints to assess inflammatory changes rely on histopathology examination of lung slices
which are assigned a qualitative description of inflammation or pathological changes. There is no
universally standardized procedure for these in vivo assessments, and they are time and resource
consuming [3,5]. Additionally, immune responses in the lungs of rats are known not to correlate well
with that of healthy human lungs [8]. Rats are obligate nose-breathers with marked differences in their
lung anatomy, physiology, and biological responses and as a result are more sensitive to inflammatory
responses compared with humans [3,9]. Studies using alveolar macrophages harvested from animals
are challenging due to the inaccessibility of cells. Additionally, the alveolar macrophage population in
rat bronchoalveolar fluid is very small, and the lavage procedure may significantly affect macrophage
health and phenotype, resulting in an insufficiently healthy cell population for further tests [10].
Therefore, human in vitro alveolar-like macrophage models may offer an advantage by generating
quantitative data allowing for detailed assessment of macrophage health and function. Furthermore,
such models allow for longitudinal assessment of morphology, functionality, and activation state of
different FM phenotypes.
Until recently, cell vacuolation in foamy alveolar macrophage responses was predominantly
assessed visually using light microscopy to image cells from bronchoalveolar lavage (BAL). Researchers
could only categorize foamy cells into two arbitrary groups: either finely or coarsely vacuolated [3].
We have developed high-throughput methodology allowing to accurate quantify a range of vacuole
characteristics including the number of vacuoles per cell, their size, and the proportion of the cell
they occupy in relation to other cellular features in a 2D cross-section of the cell [11]. Quantitative
characterization of cell vacuolation patterns alongside other markers of cell health and functionality
may help to categorize foamy alveolar macrophage responses in more detail distinguishing between
different FM phenotypes.
The aim of this study was to determine if high content image analysis could be used to categorize
morphological responses of alveolar macrophages to different stimuli and follow these changes over
time to assess the extent of reversibility. Four compounds were selected to represent different pathways
of foamy macrophage induction and control compounds: (i) amiodarone, a cationic amphiphilic
drug known to induce a FM phenotype as a result of phospholipidosis in vitro and in vivo [12]; (ii)
staurosporine, an established inducer of apoptosis which creates a foamy cell phenotype during
early stage apoptosis by increased vacuolation and membrane blebbing [13,14]; (iii) fluticasone, a
marketed corticosteroid used for inhalation therapies [15]; (iv) salbutamol, a marketed short-acting,
selective β2-adrenergic agonist used in treatment of asthma and chronic obstructive pulmonary disease
(COPD) [16]. Previous studies have established that amiodarone and staurosporine induce defined
changes in the vacuolation pattern of macrophages in vitro [11]. In contrast, salbutamol and fluticasone,
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both marketed inhaled active pharmaceutical ingredients (APIs) are not known to cause a foamy
alveolar macrophage phenotype in vitro and are used as a baseline control for the purposes of this
study [17].
2. Materials and Methods
2.1. Cell Culture
U937 human monocyte cells were cultured in RPMI-1640 cell culture medium (Sigma Aldrich,
Dorset, UK) supplemented with 10% v/v fetal bovine serum (Sigma Aldrich, Dorset, UK), 1% v/v
l-glutamine (Sigma Aldrich, Dorset, UK) and 1% v/v penicillin/streptomycin (Sigma Aldrich, Dorset,
UK) and incubated in a humidified atmosphere at 37 ◦C and 5% v/v CO2. For experiments, cells were
used between passage numbers of 2 and 20 and were seeded onto 96-well plates at density of 25,000
cells/well. For differentiation into alveolar-like macrophages, cells were incubated in complete cell
culture medium containing 100 nM phorbol myristate acetate (PMA) (Sigma Aldrich, Dorset, UK)
following methodology described previously [18–20]. The differentiation process was followed by 24 h
resting period in PMA-free complete cell culture media.
PMA-differentiated alveolar-like macrophages were exposed to 0.1–50 µM solutions of either
amiodarone, salbutamol, fluticasone, or staurosporine in complete cell culture media. The
concentrations for this study were selected from preliminary studies which indicated morphological
changes were induced (Appendix B, Figure A2) without affecting cell viability (Appendix A, Figure A1).
All compounds were purchased from Sigma Aldrich (Sigma Aldrich, Dorset, UK). After 24 h of active
pharmaceutical ingredient (API) exposure, the cell culture media was replaced with fresh media
without stimuli and cells were incubated at 37 ◦C, 5 % v/v CO2 for a further 24 or 48 h to assess
their recovery.
2.2. Assessment of Cell Vacuolation and Lipid Profiles
Fluorescence staining and imaging were performed as described previously by Hoffman et al. [11]
to determine the cellular lipid content and to assess macrophage morphology. Briefly, macrophages
were incubated simultaneously with the tested compound and HCS LipidTox Phospholipid Red dye
(Invitrogen, Renfrewshire, UK) diluted 1:1000 (according to the manufacturer’s protocol) for 24 h. After
the desired compound exposure time, the cells were fixed with 3.7% w/v paraformaldehyde containing
Hoechst 33342 (10 µg/mL) for 20 min, followed by one washing step with 100 µL phosphate buffered
saline (PBS). The cells were then incubated with Cell Mask Deep Red (Invitrogen, Renfrewshire,
UK) diluted 1:1000 (according to the manufacturer’s protocol) for 30 min at room temperature for
morphometric characterization. The cells from the assay were stored in the dark at 4 ◦C before sample
acquisition. Images were captured using the InCell Analyser 6000 (GE Healthcare, Little Chalfont,
Bucks, UK) with a 40× objective in standard 2D imaging mode with an exposure time of 0.1 s.
2.3. Quantitative High Content Analysis
Image analysis was performed using In Cell Developer Toolbox v 1.9.2, level 3 analysis (GE
Healthcare, Little Chalfont, Bucks, UK) using a method previously published by Hoffman et al. [11]. In
brief, the cell nuclear dye Hoechst 33342 was used to identify nucleated cells, while Cell Mask Deep
Red staining highlighted cytoplasm and allowed quantification of vacuoles based on negative staining.
Vacuoles within cells were identified based on negative staining and quantified using a grey scale
threshold of 19,000 to minimize any background noise and to include only true vacuole features [11].
The intracellular accumulation of phospholipids was detected and quantified by incubation with
LipidTox Phospholipid Red and reported as fluorescence intensity values [11]. Each well of the 96-well
plate was imaged using 15 fields representing in total between 500 and 1500 cells per well. Quantitative
measurements for each cell were generated from the image analysis for cell area, vacuole number per
cell, vacuole area per cell, and phospholipid content per cell.
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2.4. Statistical Analysis
All experiments were repeated independently three times (on three different cell passage numbers).
Two-way ANOVA analysis with Bonferroni multiple comparison post-hoc tests were used to assess the
statistical significance between the different cell models. Statistical significance was evaluated at a 95%
confidence level (p < 0.05). All statistical tests were performed using Graphpad Instat® version 3.06.
3. Results
3.1. Characterization of PMA-Differentiated U937 Cells
Cell data for differentiated U937 cells after 24 and 72 h was assessed to establish human alveolar-like
macrophage morphological characteristic in vitro over time in culture (Figure 1). U937 cell area ranged
from 511 to 686 µm2. The untreated macrophage-like cells demonstrated similar vacuole profiles at
both time points assessed. The average number of vacuoles per cells was 72 (±9.9) after 24 h and 81
(±5) when cells were cultured up to 72 h, while an average of 29% and 27% of cell area was occupied by
vacuoles after 24 and 72 h incubation, respectively. An average individual vacuole occupied 4.4% (±2.2)
of the cell area after 24 h incubation and 4.8% (±2.2) after 72 h. No significant differences (p > 0.05)
were observed for the cellular area and the vacuolation parameters assessed, confirming the suitability
of the model to assess changes in vacuole morphology over time.
Pharmaceutics 2020, 12, x FOR PEER REVIEW 4 of 16 
 
All experiments were repeated independently three times (on three different cell passage 
numbers). Two-way ANOVA analysis with Bonferroni multiple comparison post-hoc tests were used 
to assess the statistical significance between the different cell models. Statistical significance was 
evaluated at a 95% confidence level (p < 0.05). All statistical tests were performed using Graphpad 
Instat® version 3.06. 
3. Results 
3.1. Characterization of PMA-Differentiated U937 Cells 
Cell data for differentiated U937 cells after 24 and 72 h was assessed to establish human alveolar-
like macrophage morphological characteristic in vitro over time in culture (Figure 1). U937 cell area 
ranged from 511 to 686 µm2. The untreated macrophage-like cells demonstrated similar vacuole 
profiles at both time points assessed. The average number of vacuoles per cells was 72 (±9.9) after 24 
h and 81 (±5) when cells were cultured up to 72 h, while an average of 29% and 27% of cell area was 
occupied by vacuoles after 24 and 72 h incubation, respectively. An average individual vacuole 
occupied 4.4% (±2.2) of the cell area after 24 h incubation and 4.8% (±2.2) after 72 h. No significant 
differences (p > 0.05) were observed for the cellular area and the vacuolation parameters assessed, 
confirming the suitability of the model to assess changes in vacuole morphology over time. 
 
Figure 1. Morphometric characterization of untreated alveolar-like macrophages (U937). Cell area (a), 
number of vacuoles per cell (b), area per cell occupied by all vacuoles (c), and average area per cell 
occupied by a vacuole (d) after culture in complete cell culture medium for 24 and 72 h. All results 
are presented as mean of n = 6 ± SEM of three independent experiments. 
3.2. Phospholipidosis Phenotype 
The cationic amphiphilic API, amiodarone was used as an established inducer of 
phospholipidosis [12]. Cells were challenged with the drug for 24 h in concentrations which induced 
cellular phenotype changes but were not toxic to the cells (Appendix A, Figure A1). Macrophage-like 
cells exposed to amiodarone did not display a significant difference (p > 0.05) in cellular area nor the 
area of the cell occupied by vacuoles (Figure 2a,c). However, significant changes (p < 0.001) in the 
number of vacuoles were observed compared with untreated samples (Figure 2b). Cells challenged 
for 24 h with 5 and 10 µM amiodarone contained 1.8 (p < 0.001) and 2.6 (p < 0.001) times fewer 
vacuoles, respectively, when compared with untreated cells. To investigate cellular ability to recover 
after the initial short-term amiodarone exposure (24 h), the drug was washed out and the cells were 
further incubated in drug-free media for 24 and 48 h. The number of vacuoles returned to values of 
untreated cells after 48 h resting time. At the same time, the area of the cell occupied by vacuoles was 
unchanged, which suggests that vacuoles were smaller in size after removal of the stimulus. After 48 
h in amiodarone-free media macrophage morphology resembled the vacuolation pattern of 24 h 
untreated cells. Despite observed signs of morphometric recovery, the cells still accumulated 
phospholipids. Cells challenged with 10 µM amiodarone for 24 h followed by a 48 h API-free 
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Figure 1. Morphometric characterization of untreated alveolar-like macrophages (U937). Cell area (a),
number of vacuoles per cell (b), area per cell occupied by all vacuoles (c), and average area per cell
occupied by a vacuole (d) after culture in complete cell culture medium for 24 and 72 h. All results are
presented as mean of n = 6 ± SEM of three independent experiments.
3.2. Phospholipidosis Phenotype
The cationic amphiphilic API, amiodarone was used as an established inducer of
phospholipidosis [12]. Cells were challenged with the drug for 24 h in concentrations which induced
cellular phenotype changes but were not toxic to the cells (Appendix A, Figure A1). Macrophage-like
cells exposed to amiodarone did not display a significant difference (p > 0.05) in cellular area nor the area
of the cell occupied by vacuoles (Figure 2a,c). However, significant changes (p < 0.001) in the number of
vacuoles were observed compared with untreated samples (Figure 2b). Cells challenged for 24 h with 5
and 10 µM amiodarone contained 1.8 (p < 0.001) and 2.6 (p < 0.001) times fewer vacuoles, respectively,
when compared with untreated cells. To investigate cellular ability to recover after the initial short-term
amiodarone exposure (24 h), the drug was washed out and the cells were further incubated in drug-free
media for 24 and 48 h. The number of vacuoles returned to values of untreated cells after 48 h resting
time. At the same time, the area of the cell occupied by vacuoles was unchanged, which suggests
that vacuoles were smaller in size after removal of the stimulus. After 48 h in amiodarone-free media
macrophage morphology resembled the vacuolation pattern of 24 h untreated cells. Despite observed
signs of morphometric recovery, the cells still accumulated phospholipids. Cells challenged with 10
µM amiodarone for 24 h followed by a 48 h API-free incubation period displayed 2.9 (p < 0.001) times
higher phospholipid content when compared with untreated cells (Figure 2d).
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Figure 2. Characteristics of alveolar-like macrophages (U937) ith an a iodarone-induced
phospholipidosis phenotype. Cells were exposed to phospholipidosis-inducer a iodarone at
concentrations of 5 (orange bars) and 10 µM (purple bars) for 24 h followed by recovery (R) in
the absence of the stimulus for 24 and 48 h. Cell area (a), number of vacuoles per cell (b), area per cell
occupied by all vacuoles (c), and relative change of cellular phospholipid content (d) were quantified
and presented as mean ± SEM of three independent experiments. * indicates p < 0.05; *** indicate
p < 0.001.
3.3. Pro-Apoptotic Phenotype
Staurosporine, a known pro-apoptotic agent, induced the process of cell death, which was reflected
in the cell morphometric parameters. U937 cells treated with staurosporine displayed significantly
reduced (p < 0.001) cellular area to 12% after 24 h incubation (Figure 3a). The cells significantly
reduced in size (p < 0.001), which is a characteristic feature of apoptosis. Staurosporine treatment
also resulted in a significant decrease (p < 0.001) in the number of vacuoles per cell from 72 (±10)
(untreated cells) to nine (±2) after 24 h exposure. These observations were not reversed after the
removal of staurosporine from the culture conditions and the number of vacuoles per cell remained 9
(±11) (Figure 3b). Similarly, the cell area occupied by vacuoles significantly decreased (p < 0.001) after
24 h from 29% (±3.2) (untreated cells) to 9.8% (±1.4) and remained unchanged after removal of the
stimulus from the culture media (Figure 3c).
Pharmaceutics 2020, 12, 262 6 of 15
Pharmaceutics 2020, 12, x FOR PEER REVIEW 6 of 16 
 
 
Figure 3. Characteristics of alveolar-like macrophages (U937) with a staurosporine-induced pro-
apoptotic phenotype. Cells were exposed to apoptosis inducer staurosporine at concentrations of 0.1 
(orange bars) and 1 µM (purple bars) for 24 h followed by recovery (R) in the absence of the stimulus 
for 24 and 48 h. Cell area (a), number of vacuoles per cell (b), area per cell occupied by all vacuoles 
(c), and relative change of phospholipid cellular content (d) were quantified and presented as mean 
± SEM of three independent experiments. * indicates p < 0.05; *** indicate p < 0.001. 
3.4. Corticosteroid Phenotype 
Fluticasone propionate is a glucocorticosteroid API used in treatment of inflammation in various 
diseases, including such lung conditions as asthma or COPD [15]. In this study, it did not induce 
significant changes (p > 0.05) in U937-derived macrophage morphology (Figure 4a–c). However, 
significant changes were noted in cellular phospholipid content (Figure 4d). Initially, after 24 h, 
fluticasone did not affect phospholipid content. However, elevated phospholipid content was noted 
following drug wash-out; 2.6 (p < 0.001) and 1.8 (p < 0.01) times higher after 24 and 48 h recovery, 
respectively (Figure 4d). 
Figure 3. Characteristics of alveolar-like macrophages (U937) with a staurosporine-induced
pro-apoptotic phenotype. Cells were exposed to apoptosis inducer staurosporine at concentrations
of 0.1 (orange bars) and 1 µM (purple bars) for 24 h followed by recovery (R) in the absence of the
stimulus for 24 and 48 h. Cell area (a), number of vacuoles per cell (b), area per cell occupied by all
vacuoles (c), and relative change of phospholipid cellular content (d) were quantified and presented as
mean ± SEM of three independent experiments. * indicates p < 0.05; *** indicate p < 0.001.
3.4. Corticosteroid Phenotype
Fluticasone propionate is a glucocorticosteroid API used in treatment of inflammation in various
diseases, including such lung conditions as asthma or COPD [15]. In this study, it did not induce
significant changes (p > 0.05) in U937-derived macrophage morphology (Figure 4a–c). However,
significant changes were noted in cellular phospholipid content (Figure 4d). Initially, after 24 h,
fluticasone did not affect phospholipid content. However, elevated phospholipid content was noted
following drug wash-out; 2.6 (p < 0.001) and 1.8 (p < 0.01) times higher after 24 and 48 h recovery,
respectively (Figure 4d).
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[16]. Similarly, to fluticasone, salbutamol did not affect cell morphology, nor the cellular 
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Figure 4. Characteristics of macrophages (U937) with a fluticasone-induced corticosteroid phenotype.
Cells were exposed to a steroid (fluticasone propionate) at concentrations of 10 (orange bars) and 50 µM
(purple bars) for 24 h followed by recovery (R) in the absence of the stimulus for 24 and 48 h. Cell area
(a), number of vacuoles per cell (b), area per cell occupied by all vacuoles (c), and relative change in
cellular phospholipid content (d) were quantified and presented as mean ± SEM of three independent
experiments. * indicates p < 0.05; ** indicate p < 0.01; *** indicate p < 0.001.
3.5. β2-Agonists Phenotype
Salbutamol is a β2-agonist used as bronchodilator to relieve symptoms of asthma and COPD [16].
Similarly, to fluticasone, salbutamol did not affect cell morphology, nor the cellular phospholipid
content (Figure 5).
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followed by recovery (R) in the absence of the stimulus for 24 and 48 h. Cell area (a), number of vacuoles
per cell (b), area per cell occupied by all vacuoles (c), and relative change of cellular phospholipid
content (d) were quantified and presented as mean ± SEM of three independent experiments.
4. Discussion
Cellular recovery and resilience to toxic insult has not been studied to a great extent in in vitro
toxicology testing. The concept of cellular resilience has been described by Smironova et al. [21],
defined as the cell’s ability to cope with any perturbation or environmental changes and recover. The
authors hypothesized that cells can overcome low-dose toxic effects and become either resilient or
more susceptible to subsequent exposure [21]. In this study human monocyte-derived alveolar-like
macrophages were used to determine whether effects of short-term (24 h) drug exposure were
permanent or reversible.
The term “foamy macrophage” describes lung macrophages with highly granular or vacuolated
cytoplasmic appearance when viewed under a light microscope. The term “vacuoles” used in this
study refers to morphological feature of a cell and includes endosomes, lysosomes, as well as lipid
droplets. These vacuolated macrophages are typically described also as enlarged when compared
to non-vacuolated cells [3]. The majority of studies reporting alveolar macrophage morphology
describe qualitative observations. Usually, the morphological changes resulting from treatment with
various compounds are so pronounced that quantification may seem unnecessary. For example,
the loss of cell volume or cell shrinkage, alongside nuclear condensation, are the predominant
signatures of apoptosis [22]. Such apoptotic characteristics can be observed using light or fluorescent
microscopy [23]. However, practice is required to accurately identify the different types of deteriorated
cells. Furthermore, some morphological changes may be difficult to interpret and determining
the specific process responsible for altered morphology is challenging using the current, standard
techniques [3,4]. Currently, FM appearance is assessed only by light microscopy as one of the endpoints
of histopathological studies [4]. Moreover, the macrophage vacuolation patterns of primary cells
obtained from tested animals have not been described in detail before. The only differentiation that
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has been made to-date was for finely and coarsely vacuolated cells and was based on light microscopy
images [3].
The high content image analysis technique reported in this study demonstrates it is possible to
measure detailed morphological characteristics including cellular area, report the number of vacuoles,
and quantify the area of the cell occupied by vacuoles rapidly. Furthermore, such parameters can be
assessed over a time course, which may further help to determine if a particular phenotype is adaptive
or adverse. Quantitative determination of cellular morphology, including cell vacuolation pattern,
employed in the early phase of drug development may help to identify FM-inducing compounds
early so that the number of such compounds entering in vivo safety trials would be reduced. The
majority of in vitro methodologies currently employed for inhaled safety assessment use short-term,
single high-dose exposures and only consider the acute cellular response [24,25]. Whilst these test
conditions may capture early cellular responses the significance of these effects on medium-long term
cell health and function are not considered. As a result, consideration of the responses being reversible
and a normal adaptive response to a given stimuli or chronic consequence of exposure are overlooked.
Employment of more accurate and sensitive techniques, such as high content image analysis, in early
in vitro studies would allow for longitudinal studies of a xenobiotic (e.g., API) toxicity, as well as
potential cellular recovery to better inform decision making.
High content analysis employed in this study permitted a more detailed classification of FM
responses than light microscopy. Whilst images taken using light microscopy permit classification
of “foamy” vs. “non-foamy” cells, the current study demonstrates that detailed morphology and
vacuolation parameters can be acquired using high content image analysis techniques to elucidate the
mechanism of cellular response to a drug challenge (phospholipidosis vs. apoptotic pattern). Moreover,
changes can be tracked over time which gives an opportunity to observe how cells respond to stimuli
and whether any changes in cell morphology can be potentially reversible.
4.1. Phospholipidosis Phenotype Was Not Destructive for Macrophages
The induction of phospholipidosis by amiodarone is well-established [26] and was also confirmed
in the current study. The postulated mechanism of FM development accompanying phospholipidosis is
based on the ability of the amiodarone molecule to bind to phospholipids and prevent enzyme-mediated
metabolism, as well as direct inhibition of phospholipases themselves [27,28]. In this study, cellular
phospholipid content was measured using a standard indirect method employing a fluorescent dye
(HCS LipidTox Phospholipid Red). The recent publication by Patel et al. confirmed that this technique
reflects the true phospholipid content in a cell as quantified using mass spectrometry imaging for cells
exposed to amiodarone, and the binding of the fluorescent dye was not directly affected by presence of
the drug [26]. Phospholipid accumulation was observed at both concentrations tested (5 and 10 µM)
with no detrimental impact on cell health (Appendix A, Figure A1). API-induced phospholipidosis is
a condition defined by the appearance of intracellular accumulation of phospholipids and lamellar
bodies [29]. There are studies showing that alveolar macrophages have the ability to scavenge lamellar
bodies and become foamy when completely packed by lipids [27]. Phospholipids are accumulated in a
time- and dose-dependent manner. The biological consequence of phospholipid accumulation in the
lungs has not been evaluated but it is usually linked to cellular toxicity. However, a review by Anderson
and Barlock suggested that phospholipidosis might be a part of a detoxification mechanism to protect
cells from xenobiotics [29]. Effects of amiodarone-induced phospholipidosis on alveolar macrophages
has been reported and Reasor et al. [30] concluded that amiodarone does not impair pulmonary host
defense processes. Moreover, it may be associated with augmentation of some activities [30]. In this
study, macrophages exposed to amiodarone showed increased vacuolation, which was reflected in
fewer but larger vacuoles after an initial 24 h exposure. The vacuolation pattern resumed that of
untreated cells after the recovery time. Despite this morphometric reversibility, cells still accumulated
phospholipids. Similar findings have been reported previously in rat alveolar macrophages exposed to
another cationic, amphiphilic API, chlorphentermine [31]. Despite biochemical recovery of alveolar
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macrophages after 12 days in vitro culture, a moderate level of lamellar bodies was still present
in macrophages [31]. Prolonged phospholipid accumulation, even after an API wash out, may
be due to potential intracellular API retention and further release from the multiwell plate itself.
Kramer et al. [32] studied the distribution of compounds in the in vitro system, measured by the
concentration of APIs in cells, multiwell plate plastic, and medium. Results indicated that lipophilic
APIs bind significantly to plastic labware [32]. Additionally, some compounds, including amiodarone,
accumulate significantly in the cell over time [32,33]. It has been speculated that highly lipophilic
amiodarone targets and accumulates in cellular phospholipid bilayer and interferes with the fatty acyl
alignment [34]. Moreover, some metabolites of amiodarone have been found to contribute towards
alveolar macrophage toxicity [33].
4.2. Apoptotic Phenotype Was Not Reversible
Staurosporine is a very potent compound used in many studies as positive control for the
process of programmed cell death (apoptosis) [35]. Early during the initiation of apoptosis, cells
start to show protrusions of the plasma membrane commonly referred to as blebs [36]. The cellular
area is decreased, and finally the blebs separate forming apoptotic bodies densely packed with
cellular organelles and nuclear fragments [37]. The shrinkage of the cells, blebbing, and forming
of apoptotic bodies can be observed using light microscopy [22,36]. In this study, cells exposed to
staurosporine were smaller in size with reduced numbers of vacuoles and a smaller cell area occupied
by vacuoles. These morphological changes are in agreement with reported descriptions of apoptotic
cell morphology where dense cytoplasm and tightly packed organelles are also observed [37]. These
changes were observed regardless of time point, or cell acute or recovery status. It has been reported
that apoptosis can be reversed depending on the pathway which it has been activated (e.g., early stages
of p53-induced apoptosis are reversible [38]) or how early a stimuli has been removed [39]. There is
evidence that dying cancer cells can regain their normal morphology and proliferate after removal of
apoptotic inducers [39]. In this study, staurosporine-induced apoptosis resulted in irreversible changes.
Staurosporine acts through activation of caspase cascade pathway [40,41], which when activated is
considered unstoppable [37]. Further studies are therefore required to identify a “cellular checkpoint”
that, once crossed, makes changes persistent.
4.3. Corticosteroid and β2-Agonist Phenotypes Resolve over Time
Fluticasone propionate (glucocorticosteroid) and salbutamol hemisulfate (β2-agonist) are both
routinely used for the treatment of lung disorders including COPD and asthma [42]. Fluticasone has
anti-inflammatory properties [43], while salbutamol is used as bronchodilator [44]. Both APIs have
been available on the market for more than 30 years and can be co-administered together or used as a
single-agent treatment [45].
It has been demonstrated that the FM responses associated with the in vivo administration
of corticosteroids to animals were located at the bronchoalveolar junctions and are linked with
accumulation of various lipids [4]. The in vitro results of fluticasone-induced macrophage response
are partly in agreement with in vivo findings. Although morphometric changes were not observed
and the presence of foamy macrophages was not confirmed in the U937-derived in vitro macrophage
model, it was shown that 50 µM concentration of fluticasone increased phospholipid accumulation
following 24 + 48 h API incubation. Lewis et al. argued that corticosteroid-induced FM responses
were not progressive in animal models [4]. The results of the current in vitro study also suggest
that corticosteroid macrophage phenotype may be resolved over time, since the accumulation of
phospholipids was significantly (p < 0.001) reduced the longer the stimulus was removed.
Similarly, the in vivo administration of β2-agonists may induce FM response located at the
bronchoalveolar junctions and is linked with accumulation of surfactant phospholipids [4]. Salbutamol
treatment in vitro did not confirm these findings, as no FM morphology was observed, nor significant
changes in phospholipids accumulation.
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Normal physiological changes to the morphology of alveolar macrophages is anticipated as a
response to non-hazardous and toxic inhaled substances. This study has demonstrated that minor
changes in macrophage phenotypes can be induced from exposure to APIs which have been available
on the market for decades (e.g., fluticasone, salbutamol) and have considerable safety data in humans.
High content image analysis has allowed these cellular responses to be quantified, showing marked
differences between cell responses to different stimuli and demonstrate the ability to monitor these
changes over time. This technique may make it possible to ascertain a threshold of where a cellular
response changes from a normal adaptive response to an adverse event.
5. Conclusions
This work provides a useful contribution to better understanding the foamy macrophage phenotype
associated with API stimulation. Potential differences in alveolar macrophage responses to several
compounds were assessed and how these changes may resolve over time. Collectively, our results
indicate that FM phenotypes may resolve differentially, leading the cell either to apoptosis or adaptive
changes. The fate of the affected cell is determined by its mechanism of action. Our study provides one of
the first insights into the reversibility of FM changes which in turn may aid a more relevant FM response
classification and enhance decision making in the process of new inhaled medicines development.
Further research is needed to better understand whether resilience mechanisms are beneficial or
detrimental to cells in the long-term. Prior stimulation can lead to different responses to subsequent
stimuli. Macrophages after recovery may be either more resistant or susceptible to further exposure (via
activation of cell survival/death pathways, changes in gene expression, or epigenetic modifications).
Furthermore, permanent activation or inhibition of specific pathways may contribute to disease
pathology. Previous inflammatory episodes may critically modify function and reactivity of cells.
Further studies will investigate if resting alveolar macrophages retain the same responsiveness to
stimuli as non-stimulated previously cells.
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Appendix A
Cell viability was determined by the quantification of number of cells exposed to a drug and
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Figure A1. Effect of amiodarone (a), staurosporine (b), fluticasone (c), and salbutamol (d) on 
macrophage (U937) viability. The results are expressed as the percentage of treated cells with respect 
to the untreated control. Data is presented as mean ± SEM of three independent experiments. * 
indicates p < 0.05; *** indicate p < 0.001. 
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Figure A1. Effect of amiodarone (a), staurosporine (b), fluticasone (c), and salbutamol (d) on macrophage
(U937) viability. The results are expressed as the percentage of treated cells with respect to the untreated
control. Data is presented as mean ± SEM of three independent experiments. * indicates p < 0.05;
*** indicate p < 0.001.
Appendix B
Representative images of various macrophage morphometric phenotypes are presented in
Figure A2.
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Figure B1. Representative fluorescence microscopy images of human alveolar-like macrophages U937 
untreated (panel a), exposed to various concentrations of amiodarone (panel b), staurosporine (panel 
c), fluticasone (panel d), and salbutamol (panel e). Cells were stained with Hoechst 33342 (nuclei, in 
blue) and Cell Mask Deep Red (cytoplasm, in red). Images were acquired by InCell Analyser 6000 
with 40× objective lens. 
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